Rectal spacers in high-dose-rate-brachytherapy: Optimizing peripheral zone radiation delivery
Brachytherapy · 2026
DOI: 10.1016/j.brachy.2025.10.014 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brachytherapy, 2026. Verfasst von Christopher A Cronkite und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Molecular Biology, Baylor College of Medicine, Houston, TX. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Brachytherapy, Rectum. Die Arbeit nennt 27 Literaturangaben. Gefördert von: Houston Methodist Hospital.
Abstract (Originalsprache)
BACKGROUND: The utilization of rectal spacers (RS) in prostate cancer treated with definitive radiotherapy has been shown to provide rectal dose sparing, decreased rectal toxicity, and improved gastrointestinal quality-of-life metrics. This dose-sparing effect presents an opportunity for dose escalation to the prostate, potentially enhancing clinical and biochemical outcomes while minimizing adverse effects. Although the influence of RS on overall prostate dosimetry has yielded mixed findings, the specific impact on radiation delivery to the predominantly tumorigenic peripheral zone (PZ) remains largely unexamined. This study aims to evaluate the effects of RS on PZ dosimetry in prostate brachytherapy. METHODS: A single-institution, retrospective analysis was conducted on patients who received two-fraction high-dose-rate brachytherapy (HDR-BT) for localized prostate cancer. Dosimetric parameters and biochemical outcomes were compared between consecutive patients who received intraoperative RS (RS+) and those who did not (RS-). Additional subset analysis was performed stratifying by prostate size. Comparisons were performed using the Mann-Whitney U test. Dosimetric parameters were assessed for the prostate, planning target volume, PZ, and organs at risk (OAR). RESULTS: Between January 2020 and July 2024, a total of 92 patients who underwent HDR-BT were identified, of whom 46 (50%) were RS+. The contoured volumes of the prostate and PZ were comparable between the RS- and RS+ cohorts, with a median of 38.5 vs. 34.96 cm3 (p = 0.4475) and 11.25 vs. 10.25 (p = 0.1964), respectively, for the prostate and PZ. However, median PZ D90 was significantly higher in RS+ patients compared to RS- (RZ+ 115.65% vs. 110.25%, p < 0.0001). The increase in PZ D90 in the RS+ group was more pronounced in patients with smaller prostates (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Biochemistry and Molecular Biology, Baylor College of Medicine, Houston, TX.
- Department of Radiation Oncology, Washington University in St. Louis, St. Louis, MO.
- Department of Radiation Oncology, Houston Methodist, Houston, TX.
- Department of Radiation Oncology, Houston Methodist, Houston, TX. Electronic address: AMFarach@houstonmethodist.org.
Förderung
- Houston Methodist Hospital
Zitieren
APA
Cronkite, C. A., Lakomy, D., Baghwala, A., Pino, R., & Farach, A. M. (2026). Rectal spacers in high-dose-rate-brachytherapy: Optimizing peripheral zone radiation delivery. Brachytherapy. https://doi.org/10.1016/j.brachy.2025.10.014
Vancouver
Cronkite CA, Lakomy D, Baghwala A, Pino R, Farach AM. Rectal spacers in high-dose-rate-brachytherapy: Optimizing peripheral zone radiation delivery. Brachytherapy. 2026. doi:10.1016/j.brachy.2025.10.014
BibTeX
@article{Cronkite2026,
author = {Cronkite, Christopher A and Lakomy, David and Baghwala, Arjit and Pino, Ramiro and Farach, Andrew M},
title = {Rectal spacers in high-dose-rate-brachytherapy: Optimizing peripheral zone radiation delivery},
journal = {Brachytherapy},
year = {2026},
doi = {10.1016/j.brachy.2025.10.014}
}
EUVIMED